The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Open accessAbstract
BACKGROUND: , locking it in its inactive state. Adagrasib showed clinical activity and had an acceptable adverse-event profile in the phase 1-1b part of the KRYSTAL-1 phase 1-2 study. METHODS: -mutated non-small-cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy and anti-programmed death 1 or programmed death ligand 1 therapy. The primary end point was objective response assessed by blinded independent central review. Secondary end points included the duration of response, progression-free survival, overall survival, and safety. RESULTS: -mutated NSCLC had been treated (median follow-up, 12.9 months); 98.3% had previously received both chemotherapy and immunotherapy. Of 112 patients with measurable disease at baseline, 48 (42.9%) had a confirmed objective response. The median duration of response was 8.5 months (95% confidence interval [CI], 6.2 to 13.8), and the median progression-free survival was 6.5 months (95% CI, 4.7 to 8.4). As of January 15, 2022 (median follow-up, 15.6 months), the median overall survival was 12.6 months (95% CI, 9.2 to 19.2). Among 33 patients with previously treated, stable central nervous system metastases, the intracranial confirmed objective response rate was 33.3% (95% CI, 18.0 to 51.8). Treatment-related adverse events occurred in 97.4% of the patients - grade 1 or 2 in 52.6% and grade 3 or higher in 44.8% (including two grade 5 events) - and resulted in drug discontinuation in 6.9% of patients. CONCLUSIONS: -mutated NSCLC, adagrasib showed clinical efficacy without new safety signals. (Funded by Mirati Therapeutics; ClinicalTrials.gov number, NCT03785249.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These results indicate the rapid development of acquired resistance to KRAS G12C inhibitors [18, 26, 27, 49].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The data from both CodeBreak 100 for sotorasib and KRYSTAL-1 for adagrasib led to the approval of these inhibitors to treat G12C-mutant NSCLC [51,53,94].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [94]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In clinical trials, the inactive-state KRASG12C mutant-specific inhibitors adagrasib (MRTX849) and sotorasib (AMG510) achieved 37–43% anti-tumor response rates in NSCLC patients with most experiencing disease progression 6–12 months after initiation of therapy7–9.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“STK11/LKB1 loss and KEAP1 mutations may contribute to lack of response to different therapies including anti-PD-(L)1 immune checkpoint inhibitors9,10 and KRASG12C inhibitors3,4.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For adagrasib, an ORR was 23.0% in CRC, compared to 42.8% in NSCLC (Table 1) [27, 48].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Colorectal cancer, in particular, has a markedly lower response rate to KRAS G12C inhibitors compared to non-small cell lung cancer.”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, the therapeutic response to KRAS G12C inhibition was short-lived, with quick emergence of acquired resistance.”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Even in NSCLC patients, the response to KRAS G12C inhibitors was often short-lived, with a DOR of 10.9–11.1 months and PFS of 6.3–6.8 months for sotorasib, and a DOR of 8.5 months and PFS of 6.5 months for adagrasib (Table 1).”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, sotorasib, adagrasib, and divarasib monotherapies have demonstrated objective response rates ranging from 7.1% to 53.4% and median progression-free survival of 4.0-13.1 months, 13-20”
From Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer (2024) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The overall response rate of inactive-state KRASG12C inhibitors sotorasib and adagrasib in patients with KRASG12C mutant NSCLC is 37-43%, a major advance albeit with significant room for improvement7,8.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“This is further supported by a numerically higher ORR seen with divarasib in patients with non-small cell lung cancer (56.4%) compared with sotorasib (37% in a phase 2 trial and 28% in a phase 3 trial) and adagrasib (43% in a phase 2 trial)11,23–25.”
From Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2024) · cites this paper as [24]
The cited source says what the claim attributes to it.
In the citing paper
“Clinical studies have shown that many patients with KRAS G12C cancers did not respond to sotorasib and adagrasib.”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Because KRAS mutations are often clonal founder events, mutant KRAS ctDNA can serve as a highly informative molecular marker for tumor burden, treatment response, minimal residual disease, and emergence of resistance [29,47,77,78].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [29]
Experimental — accuracy not yet measuredIn the citing paper
“Adagrasib is a selective, irreversible inhibitor of KRASG12C and has favorable properties, including long half-life (23 hours), dose-dependent pharmacokinetics, and central nervous system penetration (3–5).”
From Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer (2024) · cites this paper as [4]
In the citing paper
“Adagrasib is a selective, irreversible inhibitor of KRASG12C and has favorable properties, including long half-life (23 hours), dose-dependent pharmacokinetics, and central nervous system penetration (3–5).”
From Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer (2024) · cites this paper as [4]
In the citing paper
“Adagrasib is a selective, irreversible inhibitor of KRASG12C and has favorable properties, including long half-life (23 hours), dose-dependent pharmacokinetics, and central nervous system penetration (3–5).”
From Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer (2024) · cites this paper as [4]
In the citing paper
“Adagrasib is a selective, irreversible inhibitor of KRASG12C and has favorable properties, including long half-life (23 hours), dose-dependent pharmacokinetics, and central nervous system penetration (3–5).”
From Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer (2024) · cites this paper as [4]
In the citing paper
“Adagrasib is a selective and irreversible oral small-molecule inhibitor of the mutant KRAS G12C protein18 and was recently approved by the FDA for treatment of NSCLC who have received at least 1 prior systemic therapy19.”
From Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients (2023) · cites this paper as [19]
In the citing paper
“This subset of patients that were evaluable for longitudinal KRASG12C ctDNA response in Cohort A exhibited a slightly higher ORR (56.4%, 22/39 cycle ctDNA response evaluable) compared to Cohort A overall (50.5%, 48/95 RECIST 1.1 evaluable patients)19”
From Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients (2023) · cites this paper as [19]
In the citing paper
“Updated data from 116 patients with previously treated NSCLC included in a registrational phase II cohort of KRYSTAL-1 showed an ORR of 42.9%, a DCR of 79.5%, median DoR of 8.5 months, median PFS of 6.5 months, median OS of 12.6 months and estimated 1-year OS of 50.8% with adagrasib83.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [83]
In the citing paper
“While these drugs clearly have clinical activity, overall response rates (30-40%) and disease control (~60%) in NSCLC are modest and transient, with median duration less than one year (9,10).”
From Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy (2023) · cites this paper as [10]
In the citing paper
“Multiple mechanisms of intrinsic and acquired resistance (10,12,13), have been identified; hence, drug combinations will likely be needed to maximize the clinical efficacy of G12Cis (and probably other, emerging KRAS inhibitors) in NSCLC and other diseases.”
From Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy (2023) · cites this paper as [10]
In the citing paper
“The phase II portion of KRYSTAL-2 included 116 patients with KRAS G12C NSCLC treated with adagrasib 600 mg bid [100]. All patients had prior platinum-doublet chemotherapy and 98.3% had received both chemotherapy and checkpoint inhibitor therapy. With a median follow-up of 12.9 months, the ORR was 42.9%.”
From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [100]
In the citing paper
“Among 33 patients with previously treated, stable central nervous system metastases, the intracranial confirmed objective response rate was 33.3% (95% CI, 18.0–51.8) [100].”
From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [100]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Self-citationGaron, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60845-x · Cited by 1,309
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
Self-citationAllele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691
Fell, J. B., Fischer, J. P., Baer, B. R., Blake, J. F., Bouhana, K., Briere, D. M., Brown, K. D., Burgess, L. E., Burns, A. C., Burkard, M. R., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02052 · Cited by 653
Self-citationRapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Xue, J. Y., Zhao, Y., Aronowitz, J., Mai, T. T., Vides, A., Qeriqi, B., Kim, D., Li, C., de Stanchina, E., Mazutis, L., et al. (2020) · Nature · doi:10.1038/s41586-019-1884-x · Cited by 543
Mehta, M. P., Rodrigus, P. T. R., Terhaard, C. H. J., Rao, A. R., Suh, J. H., Roa, W., Souhami, L., Bezjak, A., Leibenhaut, M. H., Komaki, R. U., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.122 · Cited by 466
Targeting the untargetable KRAS in cancer therapy
Liu, P., Wang, Y., & Li, X. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.03.002 · Cited by 366
Flagged first, then by citations
Research works printed but not linked: 1
- Mirati Therapeutics. U.S. Food and Drug Administration (FDA) accepts Mirati Therapeutics’ new drug application for adagrasib as treatment of previously treated KRASG12C-mutated non-small cell lung cancer. February 15 2022 (https://ir.mirati.com/press-releases/press-release-details/2022/U.S.-Food-and-Drug-Administration-FDA-Accepts-Mirati-Therapeutics-New-Drug-Application-for-Adagrasib-as-Treatment-of-Previously-Treated-KRASG12C-Mutated-Non-Small-Cell-Lung-Cancer/default.aspx).
Cited by
Sorted by citations
Items 801–900 of 1,002
Luciano, A., Liguori, L., Polcaro, G., Sabbatino, F., & Pepe, S. (2023) · Preprints.org · doi:10.20944/preprints202306.0535.v1
Luciano, A., Liguori, L., Polcaro, G., Sabbatino, F., & Pepe, S. (2023) · Preprints.org · doi:10.20944/preprints202307.2129.v1
Nagahama, K., Isomura, A., Hayashi, A., Momomura, M., Kobayashi, Y., & Shibahara, J. (2023) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2023.101252
P25-14: Hepatic safety assessment of covalent inhibitor drug candidates
Amberntsson, S., Chouhan, B., Foster, A. J., Smith, G., Wilkinson, S., Harlfinger, S., Kavanagh, S. L., & Williams, D. P. (2023) · Toxicology Letters · doi:10.1016/s0378-4274(23)00938-4
Other molecular cohorts including ROS1, BRAF, HER2, MET, NTRK, RET, KRAS
Lander, E. M., & Cass, A. S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-69573-2.00021-8
Oncogenèse pulmonaire et bases biologiques des traitements ciblés
Blons, H., Mansuet‐Lupo, A., Garinet, S., Wislez, M., Mascaux, C., Levallet, G., & Leroy, K. (2023) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(23)00124-6 · Cited by 1
Autres cibles addictives (KRAS, RET, HER2, NTRK…)
Planchard, D., Simon, É., Abdayem, P., & Greillier, L. (2023) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(23)00140-4
Treatment of Stage IV Non-small Cell Lung Cancer
Sun, T. Y., & Das, M. S. (2023) · Respiratory medicine · doi:10.1007/978-3-031-38412-7_8
Horinaka, M., Yoshimura, A., Yaoi, T., Ono, H., Itoh, K., Yamada, T., Takayama, K., & Sakai, T. (2023) · Research Square · doi:10.21203/rs.3.rs-3558262/v1
Recurrent and Metastatic Non‐Small Cell Lung Cancer
Julia, J., Bodor, N. S., & Borghaei, A. (2023) · Wiley eBooks · doi:10.1002/9781119823766.ch7
A case description of pulmonary enteric adenocarcinoma with KRAS G12D mutation
Fan, F., & Zhang, H. (2023) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-23-369
Making incurable pancreatic cancer curable
An, J., Xie, D., & Xie, K. (2023) · Malignancy Spectrum · doi:10.1002/msp2.19
Mechanisms of Resistance in Non-Small Cell Lung Cancer
Alexandra-Maria, H. O. Z. A., PATRASCU, A.-D., Orlov-Slavu, M. C., HOROMNEA, R., & Niţipir, C. (2023) · Medicina Moderna - Modern Medicine · doi:10.31689/rmm.2023.30.4.269
Case of lung fine needle aspiration showing mucinous cells and extracellular mucin
Saliba, M., Smithgall, M. C., Saqi, A., Crapanzano, J. P., & Sung, S. (2024) · Diagnostic Cytopathology · doi:10.1002/dc.25294
Fifteen years of precision medicine in the lung cancer management: Perspectives and Challenges
Ferreira, C. G., Marchi, P. D., Veloso, G. G. V., Reis, M. X., Barcelos, I. F., & Montella, T. C. (2024) · Medical Research Archives · doi:10.18103/mra.v12i2.5169 · Cited by 2
CasRx-Based Kras G12D Silencing for In Vivo Tumor Inhibition in Spontaneous Lung AdenocarcinomaPreprint
Wang, X., Liu, F., Xu, L., Shi, Y., Zhang, L., Chen, F., Gu, S., Jin, Z., Zhou, H., Li, T., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4041534/v1
Shen, F., Guo, W., Song, X., & Wang, B. (2023) · Figshare · doi:10.6084/m9.figshare.23498186
Sharma, S., Agrawal, A., Singh, A. K., & Banik, B. K. (2024) · Current Cancer Therapy Reviews · doi:10.2174/0115733947301362240330090709
Kommentar zu: Divarasib und Adagrasib: sicher und wirksam bei KRAS-G12C-positiven Tumoren?
Roderburg, C., Leyh, C., & Lüdde, T. (2024) · Gastroenterologie up2date · doi:10.1055/a-2207-8578
Zielgerichtete Therapie des nichtkleinzelligen Lungenkarzinoms
Glanemann, F., & Wiesweg, M. (2024) · Die Onkologie · doi:10.1007/s00761-024-01582-3
Oncogenèse pulmonaire : de l’altération moléculaire au cancer
Baldacci, S., Blons, H., Mascaux, C., & Leroy, K. (2024) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(24)00070-3
Autres cibles addictives (KRAS, RET, HER2, NTRK...)
Cortot, A. B., Abdayem, P., & Planchard, D. (2024) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(24)00090-9
The emergence of pan-KRAS drugs
McConnell, D. B., & Kraut, N. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00019-x
Immune-oncology potential of KRAS inhibitors
Molina‐Arcas, M., Boumelha, J., & Downward, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00013-9
Patny, A., & Simon, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00005-x
KRAS-driven cancer models for in vivo pharmacology and drug discovery
Chugh, S., Dow, L. E., Singh, M., & Aguirre, A. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00004-8
Dependence of NPPS creates a targetable vulnerability in RAS-mutant cancers
Xia, R., Zou, P., Xie, J.-T., Tang, Y., Gong, M., Fan, F., Aihemaiti, A., Liu, Y., Shen, Y. H., Zhou, B.-B. S., et al. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01409-2
CASE HISTORY: THE DISCOVERY OF KRAZATI®(ADAGRASIB) FOR THE TREATMENT OF KRASG12C-MUTATED LUNG CANCER
Marx, M. A., Hallin, J. F., Christensen, J. G., & Fell, B. (2024) · Medicinal chemistry reviews · doi:10.1021/mc-2024-vol59.ch17
Self-citationNovel Systemic Therapies for Solid Tumor Brain Metastases
Therkelsen, K. E., & Nagpal, S. (2024) · Springer eBooks · doi:10.1007/978-3-031-67878-3_49
Targeted Agents and Immunotherapy
Ranjan, T., Podder, V., & Ahluwalia, M. S. (2024) · Springer eBooks · doi:10.1007/978-3-031-67743-4_31
RASopathy Genes: Germline Risk and Somatic Cancers
Ney, G. M., Kratz, C. P., & Stewart, D. R. (2024) · Springer eBooks · doi:10.1007/978-3-031-62945-7_22
New Insights on Success and Failed Drugs
Sun, Z., & Zhou, Y. (2024) · Springer eBooks · doi:10.1007/978-981-97-7274-2_10
Sprague, D., Hart, M. G., Klein, J. S., Kounlavouth, S., Vegesna, R., Rotunno, M., Kraemer, L. D., Zhou, R., Kemp, L., Greene, A. C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.06.627073
Self-citationAdagrasib-induced photodistributed hyperpigmentation: Two case reports and pathogenetic hypothesis
Lebled, J., Claudel, J. P., Agier, M.-S., Plantier, L., Largeau, B., & Jonville‐Béra, A. ‐. (2025) · Therapies · doi:10.1016/j.therap.2024.12.014
A Phase 1/1B Trial of Pembrolizumab and Trametinib in Advanced NSCLC Enriched for KRAS Mutations
Riess, J. W., Lara, M. S., Luxardi, G., de Rodas, M. L., Shimoda, M., Kelly, K. L., Lara, P. N., Beckett, L. A., Monjazeb, A. M., Schalper, K. A., et al. (2025) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2025.100806
A clinician’s perspective: what tumor-organoid researchers ought to know
Lim, J. U. (2025) · Organoid · doi:10.51335/organoid.2025.5.e1
Therapiekonzepte sowie Prävention/Überwindung von Resistenzen
Kretzschmar, A. (2025) · Onkologische Welt · doi:10.1055/a-2495-9943
Post-marketing safety of Adagrasib: a disproportionality analysis based on the FAERS database
Shi, Z., Yu, X., Zhao, Y., Shao, K., Xu, C., & Song, Z. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2468866
Deck, S. L., Xu, M., Stankus, M., Milano, S. K., & Cerione, R. A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.27.639303
From Mechanisms to Therapeutics: Tackling Resistance in EGFR, KRAS, and ALK in NSCLC
Liu, H. (2025) · Highlights in Science Engineering and Technology · doi:10.54097/0trsfx05
Editorial: KRAS in stage IV non-small cell lung cancer
Noordhof, A. L., Blum, T. G., Hardavella, G. F., Hendriks, L. E. L., & van Geffen, W. H. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1517049
Second-line therapy for KRAS-positive metastatic non-small cell lung cancer
Svatoň, M. (2025) · Onkologie · doi:10.36290/xon.2025.007
Biomarcadores predictivos en el cáncer de pulmón. Implicaciones terapéuticas
Olmedo, M. E., Lage, Y., García-Pardo, M., Roa, J. C., Calvo, J. C., Alía, V., Barrill, A. M., González, G., & Chamorro, P. G. Y. J. (2025) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2025.03.005
Liu, Y., Dou, J., Tan, Q., Chen, S., Li, Y., Wang, R., Sun, N., & Qi, X. (2025) · Scientific Reports · doi:10.1038/s41598-025-95513-w
Михайловна, К. Т., Александровна, К. Е., Ivanov, A. V., Shishkin, A. M., Kaminsky, V. V., Knyazeva, O. B., Puchkov, I. A., & Bozhenko, K. V. (2025) · Advances in molecular oncology · doi:10.17650/2313-805x-2025-12-1-61-66
Chang, C., Liang, Y., Lin, B., Chen, K., & Yeh, K. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00609
Klußmann, M., Matijass, M., & Neundorf, I. (2025) · ChemBioChem · doi:10.1002/cbic.202401076
Targeting the Undruggable KRAS Mutation in Lung Cancer: A Review
Jones, C. A. (2024) · Premier journal of science. · doi:10.70389/pjs.100001
Prostatakarzinom: Aktuelle und zukünftige Radioligandentherapie
Rischpler, C. (2025) · Trillium Krebsmedizin · doi:10.47184/tk.2025.02.8
Fortschritte in der Therapie des mutierten NSCLC: Aktuelle Standards und zukünftige Perspektiven
Tufman, A. (2025) · Trillium Krebsmedizin · doi:10.47184//tk.2025.02.9
Vierra, M. A., Morgan, R. B., & Eng, O. S. (2025) · Personalized Medicine · doi:10.1080/17410541.2025.2532360 · Cited by 1
The Oncogenic KRAS in Solid Cancer: Functional Signaling
Kumari, A., Dan, S., Ghosh, R., Sett, S., Nanda, D., Chakrabarti, J., & Mandal, C. (2025) · Journal of Current Oncological Trends · doi:10.4103/jcot.jcot_14_24
Guo, Z. (2025) · International Journal of Radiation Research · doi:10.61186/ijrr.23.2.31
Case of KRAS G12C-Mutated AML Treated With Sotorasib
Drekolias, D., Knepper, T. C., Lovette, Q., & Sallman, D. A. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00368
Update on Drug-Induced Pneumonitis in Lung Cancer
McAvoy, K. A., & Possick, J. D. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2666-7519
Zeng, J., Li, Q., Li, K., Yang, L., Xu, L., Wang, W., Yang, K., Wei, Q., Wang, J., Zhu, C., et al. (2025) · PubMed Central · doi:10.3389/fimmu.2025.1605227
Ahn, S., Oh, T.-S., Suh, S., Jeon, J. H., Lah, S., Ryu, K., Kim, H., Lee, E. G., Lee, H., Lee, J. Y., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.31.673313
Gao, S., Luan, Y., Yu, X., Wang, L., Huang, X., Yang, J., & Liu, W. (2025) · Pharmaceuticals · doi:10.3390/ph18101431
Real-world adverse event analysis of Adagrasib: Insights from the FAERS database
Jian, S., Liang, S., Ma, X., Chen, S., Zhang, X., Lan, X., Zuo, P., Hou, E., & Tu, S. (2025) · Medicine · doi:10.1097/md.0000000000044755
Seghers, S., Compte, M. L., Fortes, F. R., Roeyen, G., Hartman, V., Hendriks, J. M., Schil, P. E. V., Komen, N., Vercammen, H., Peeters, M., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7614104/v1
Prise en charge du cancer pulmonaire non à petites cellules avec mutation de KRAS
Chour, A., Lafitte, C., Boussageon, M., Pierret, T., & Duruisseaux, M. (2025) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(25)00078-3 · Cited by 1
DaSilva, B. A., Neugut, A. I., Fojo, T., & Bates, S. E. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf336
Advances in Systemic Therapy for Lung Cancer
Lalla, M., Pan, E., Jokić, V., Jeon, H., & Halmos, B. (2025) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2025.09.005
Liu, M., Wan, S., Guo, S., Liu, J., Li, W., Wang, L., Li, F., Zhang, J., Liu, X., Liu, D., et al. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.5c00361
Self-citationFogli, S., Barberis, A., Re, M. D., Crucitta, S., Ruglioni, M., Luculli, G. I., Guglielmi, G., Scavone, C., Petrini, I., Panzeri, N., et al. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.101023
Tomaschko, M., Ng, K., Moore, C., Pillsbury, C. E., Rana, S., Campbell, J., Mukherjee, S., Mikolajczak, A., Anastasiou, P., de Castro, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.27.684825
Structure-based design and synthesis of novel highly potent and selective KRASG12C inhibitors
Gao, K., Bao, L., Li, S., Zhang, C., Xu, L., & Zhu, C. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118321
Yang, X., Zhu, J., & Wu, H. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003878
Farhat, K., Paul, M. A., Roby, L., Roberts, T. J., Landry, L. G., Hossaini, C., Sulieman, R., Lathan, C. S., Johnson, B. E., & Kehl, K. L. (2025) · JCO Oncology Practice · doi:10.1200/op-25-00280
Gan, L., Shen, J., Yao, M.-X., Chen, Z., & Zhuang, Z. (2025) · World Journal of Clinical Cases · doi:10.12998/wjcc.v13.i31.108942
Deciphering KRAS inhibitor resistance
Torphy, R. J., & Pylayeva‐Gupta, Y. (2025) · Nature Cell Biology · doi:10.1038/s41556-025-01757-z
Xu, Y., Dai, K., Chen, W., Wu, H., & Lin, P. (2025) · International Medical Case Reports Journal · doi:10.2147/imcrj.s554848
Sato, K., Akamatsu, H., Koh, Y., Ogawa, K., Isa, S.-I., Ando, M., Tamiya, A., Kubo, A., Kitagawa, C., Kawaguchi, T., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21523770
Polcaro, G., Liguori, L., Manzo, V., Chianese, A., Donadio, G., Caputo, A., Scognamiglio, G., Dell’Annunziata, F., Langella, M., Corbi, G., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25479068
Polcaro, G., Liguori, L., Manzo, V., Chianese, A., Donadio, G., Caputo, A., Scognamiglio, G., Dell’Annunziata, F., Langella, M., Corbi, G., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26697218
Shen, F., Guo, W., Song, X., & Wang, B. (2023) · Figshare · doi:10.6084/m9.figshare.23498183
Rosell, R., Lewintre, E. J., Cao, P., Cai, X., Xing, B., Ito, M., Gomez-Vazquez, J. L., Marco-Jordán, M., Fariñas, S. C., Cardona, A. F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26027462
Polcaro, G., Liguori, L., Manzo, V., Chianese, A., Donadio, G., Caputo, A., Scognamiglio, G., Dell’Annunziata, F., Langella, M., Corbi, G., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26697209
Polcaro, G., Liguori, L., Manzo, V., Chianese, A., Donadio, G., Caputo, A., Scognamiglio, G., Dell’Annunziata, F., Langella, M., Corbi, G., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26697194
Shen, F., Guo, W., Song, X., & Wang, B. (2023) · Figshare · doi:10.6084/m9.figshare.23498174
Broeker, C. D., Ortiz, M. M. O., Murillo, M. S., & Andrechek, E. R. (2023) · Figshare · doi:10.6084/m9.figshare.24266030
Polcaro, G., Liguori, L., Manzo, V., Chianese, A., Donadio, G., Caputo, A., Scognamiglio, G., Dell’Annunziata, F., Langella, M., Corbi, G., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26697221
Broeker, C. D., Ortiz, M. M. O., Murillo, M. S., & Andrechek, E. R. (2024) · Figshare · doi:10.6084/m9.figshare.24266073
Polcaro, G., Liguori, L., Manzo, V., Chianese, A., Donadio, G., Caputo, A., Scognamiglio, G., Dell’Annunziata, F., Langella, M., Corbi, G., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26697197
Polcaro, G., Liguori, L., Manzo, V., Chianese, A., Donadio, G., Caputo, A., Scognamiglio, G., Dell’Annunziata, F., Langella, M., Corbi, G., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26697203
Kotani, H., Oshima, H., Boucher, J. C., Yamano, T., Sakaguchi, H., Sato, S., Fukuda, K., Nishiyama, A., Yamashita, K., Ohtsubo, K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26265117
Additional file 1 of KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner
Laurent, P.-A., Milić, M., Quevrin, C., Meziani, L., Liu, W., Morel, D., Signolle, N., Clémenson, C., Lévy, A., Mondini, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24472444
Polcaro, G., Liguori, L., Manzo, V., Chianese, A., Donadio, G., Caputo, A., Scognamiglio, G., Dell’Annunziata, F., Langella, M., Corbi, G., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26697212
Shen, F., Guo, W., Song, X., & Wang, B. (2023) · Figshare · doi:10.6084/m9.figshare.23498171
Polcaro, G., Liguori, L., Manzo, V., Chianese, A., Donadio, G., Caputo, A., Scognamiglio, G., Dell’Annunziata, F., Langella, M., Corbi, G., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26697200
Polcaro, G., Liguori, L., Manzo, V., Chianese, A., Donadio, G., Caputo, A., Scognamiglio, G., Dell’Annunziata, F., Langella, M., Corbi, G., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26697206
Polcaro, G., Liguori, L., Manzo, V., Chianese, A., Donadio, G., Caputo, A., Scognamiglio, G., Dell’Annunziata, F., Langella, M., Corbi, G., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26697215
Shen, F., Guo, W., Song, X., & Wang, B. (2023) · Figshare · doi:10.6084/m9.figshare.23498177
Shen, F., Guo, W., Song, X., & Wang, B. (2023) · Figshare · doi:10.6084/m9.figshare.23498180
Kotani, H., Oshima, H., Boucher, J. C., Yamano, T., Sakaguchi, H., Sato, S., Fukuda, K., Nishiyama, A., Yamashita, K., Ohtsubo, K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26265024
Dang, S., Zhang, S., Zhao, J., & Li, W. (2024) · Figshare · doi:10.6084/m9.figshare.26308921
Polcaro, G., Liguori, L., Manzo, V., Chianese, A., Donadio, G., Caputo, A., Scognamiglio, G., Dell’Annunziata, F., Langella, M., Corbi, G., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25478820
Li, K., Wu, L., Wang, H., Fu, Z., Gao, J., Liu, X., Fan, Y., Qin, X., Ni, D., Wang, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26952364
Targeted therapy in biliary tract cancer
Fiocco, C., & Spencer, K. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29287-3.00015-5
Metadata
- Authors
- Jänne, P. A., Riely, G. J., Gadgeel, S. M., Heist, R. S., Ou, S.-H. I., Pacheco, J. M., Johnson, M. L., Sabari, J. K., Leventakos, K., Yau, E., Bazhenova, L., Negrao, M. V., Pennell, N. A., Zhang, J., Anderes, K., Der-Torossian, H., Kheoh, T., Velastegui, K., Yan, X., Christensen, J. G., Chao, R. C., & Spira, A. I.
- Affiliations
- From the Lowe Center for Thoracic Oncology, Dana–Farber Cancer Institute (P.A.J.), and Massachusetts General Hospital (R.S.H.) — both in Boston; the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College (G.J.R.), and Perlmutter Cancer Center, New York University Langone Health (J.K.S.), New York, and the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (E.Y.) — all in New York; the Henry Ford Cancer Institute, Detroit (S.M.G.); the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.), the University of California San Diego Moores Cancer Center, La Jolla (L.B.), and Mirati Therapeutics, San Diego (K.A., H.D.-T., T.K., K.V., X.Y., J.G.C., R.C.C.) — all in California; the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora (J.M.P.); Sarah Cannon Research Institute at...
- Roswell Park Comprehensive Cancer Center (US)
- ORCID
- Riely, Gregory J.
- Gadgeel, Shirish M.
- Heist, Rebecca S.
- Ou, Sai-Hong I.
- Johnson, Melissa L.
- Sabari, Joshua K.
- Leventakos, Konstantinos
- Yau, Edwin
- Bazhenova, Lyudmila
- Negrao, Marcelo V.
- Pennell, Nathan A.
- Zhang, Jun
- Anderes, Kenna
- Kheoh, Thian
- Velastegui, Karen
- Christensen, James G.
- Chao, Richard C.
- Spira, Alexander I.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-14
- Volume
- 387
- Issue
- 2
- Pages
- 120-131
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281650778
- Cited by
- 1,061
- References
- 27
- Citations by year
- 2026: 247 · 2025: 270 · 2024: 285 · 2023: 203 · 2022: 56
- FWCI
- 131.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Mirati Therapeutics, Inc.
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- adagrasib, KRAS G12C mutation, non-small cell lung cancer, KRAS inhibitors, objective response rate, progression-free survival, overall survival, central nervous system metastasis, treatment-related adverse events, previously treated patients
- MeSH terms
- Acetonitriles, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Piperazines, Pyrimidines, Proto-Oncogene Proteins p21(ras)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
